Biolinq Shine, Insulin Icodec, and Eli Lilly's Pipeline

from Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · host Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, explore 3 significant developments shaping diabetes care: a novel glucose-sensing technology, the return of once-weekly insulin icodec to the US Food and Drug Administration (FDA), and changes to Eli Lilly’s metabolic research pipeline.00:00:01 Introduction00:00:18 The Biolinq Shine00:05:59 The Practicality of Monitoring Glucose00:06:55 Wishlist for the Biolinq's Future00:08:38 Insulin Icodec Resubmission00:10:21 Benefits of Once-Weekly Insulin00:14:00 International Success Stories00:15:28 Eli Lilly Cancels Bimagrumab for T2D00:18:36 Bimagrumab Still in Testing for Obesity00:22:49 Outro

Episode metadata supplied by the publisher feed · Published Oct 14, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Biolinq Shine, Insulin Icodec, and Eli Lilly's Pipeline

0:00 22:58

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives?

This episode is 22 minutes long.

When was this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode published?

This episode was published on October 14, 2025.

Can I download this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!